<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04191460</url>
  </required_header>
  <id_info>
    <org_study_id>12175</org_study_id>
    <secondary_id>2019-003416-30</secondary_id>
    <nct_id>NCT04191460</nct_id>
  </id_info>
  <brief_title>Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer</brief_title>
  <acronym>GuidedbyLight</acronym>
  <official_title>Guided by Light: Optimizing Surgical Excision of Oral Cancer Using Real-time Fluorescence Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two-staged clinical trial to investigate the feasibility of intraoperative
      Fluorescence Imaging (FLI) to adequately assess tumor margins in patients with oral cancer
      using cRGD-ZW800-1.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Work package I:

      In WP-I, the preferred dose of the agent for imaging of margins in oral cancer will be
      determined. The signal-to-noise ratio will be determined in dose group A (n=7), which will
      receive 0.05 mg/kg of the tracer, 16-20 hours before surgery. After an interim evaluation of
      this ratio, the second dose group B (n=7) will receive either a higher or a lower dosage (to
      be determined) of the tracer. After inclusion of all patients (n=14), the dose with the
      highest intraoperative signal-to-noise ratio will be selected.

      Work package II:

      In WP-II, an expansion cohort (n=15) will be added to the group of patients that had received
      the selected dose in WP-I. In this group of 22 patients, it will be determined if FLI can
      improve the rate of adequate surgical resection margins. As secondary research questions, the
      following aspects will be assessed:

        -  sensitivity, specificity, positive and negative predictive values of FLI;

        -  colocalization with immunohistochemistry;

        -  change in surgical management; incremental operation time;

        -  FLI of excised cervical lymph nodes.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>WP-I: (Highest) mean tumor-to-background ratio (TBR)</measure>
    <time_frame>up to 48 ours post-dose</time_frame>
    <description>Two dosages of cRGD-ZW800-1 are tested in two groups of each 7 patients. An expansion cohort (n=15) will be added to the dose group that yields the highest TBR.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WP-II: Rate of adequate (i.e. &gt;5mm clear) tumor resection margins.</measure>
    <time_frame>through histopathology, up to max 4 weeks post-op</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>WP-II: Sensitivity, specificity, positive and negative predictive values</measure>
    <time_frame>through histopathology, up to max 4 weeks post-op</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WP-II: Co-localization of FLI with immunohistochemistry on pathology slides</measure>
    <time_frame>through histopathology, up to max 4 weeks post-op</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WP-II: Percentage of extra tissue resection based on FLI-driven frozen sections</measure>
    <time_frame>through histopathology, up to max 4 weeks post-op</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WP-II: Operation time</measure>
    <time_frame>through histopathology, up to max 4 weeks post-op</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WP-II: FLI of lymph node metastases after neck dissection</measure>
    <time_frame>through histopathology, up to max 4 weeks post-op</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">29</enrollment>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <condition>Oral Cancer</condition>
  <condition>Squamous Cell Carcinoma of the Oral Cavity</condition>
  <arm_group>
    <arm_group_label>WP-I dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n=7. Injection of 0.05 mg/kg cRGD-ZW800-1, within 16-20 hours before imaging/surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WP-I dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n=7. Injection of (to be determined) mg/kg RGD-ZW800-1, within (to be determined) hours before imaging/surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WP-II selected dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n=15: expansion cohort (n=15) will be added to the group of patients that had received the selected dose in WP-I. Injection of 0.05 ór (to be determined) mg/kg cRGD-ZW800-1, within 48 hours before imaging/surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cRGD-ZW800-1.</intervention_name>
    <description>Injection of cRGD-ZW800-1 within 48 hours before imaging/surgery</description>
    <arm_group_label>WP-I dose A</arm_group_label>
    <arm_group_label>WP-I dose B</arm_group_label>
    <arm_group_label>WP-II selected dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with biopsy-proven squamous cell carcinoma of the oral cavity, eligible for
             surgical resection of the primary tumor;

          2. ≥ 18 years of age;

          3. Before patient registration, written informed consent must be given according to
             ICH/GCP, and national/local regulations.

        Exclusion Criteria:

          1. Previous surgery, chemotherapy or radiotherapy to the oral cavity;

          2. History of a clinically significant allergy or anaphylactic reactions to any of the
             components of the agent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stijn Keereweer, MD PhD</last_name>
    <phone>010 704 13 57</phone>
    <email>s.keereweer@erasmusmc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Erasmus University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Stijn Keereweer, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Stijn Keereweer, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 5, 2019</study_first_submitted>
  <study_first_submitted_qc>December 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2019</study_first_posted>
  <last_update_submitted>December 9, 2019</last_update_submitted>
  <last_update_submitted_qc>December 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Stijn Keereweer</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>cRGD-ZW800-1</keyword>
  <keyword>fluorescence-guided surgery</keyword>
  <keyword>image-guided surgery</keyword>
  <keyword>fluorescence imaging</keyword>
  <keyword>cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Mouth Neoplasms</mesh_term>
    <mesh_term>Lip Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

